What is Intercept Pharmaceuticals?
Intercept Pharmaceuticals operates as a specialized biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapeutics for progressive non-viral liver diseases. The company's core competency lies in its deep understanding of complex hepatic pathophysiology, allowing it to advance a robust pipeline of investigational medicines. By integrating rigorous clinical research with sophisticated regulatory and market access capabilities, Intercept bridges the gap between scientific innovation and patient care. Its market position is defined by a focused therapeutic strategy that targets high-need areas within hepatology, ensuring that its drug development efforts remain aligned with evolving clinical standards and global healthcare requirements.
How much funding has Intercept Pharmaceuticals raised?
Intercept Pharmaceuticals has raised a total of $1.5B across 11 funding rounds:
Series B
$25M
Series C
$30M
Stock Offering
$75M
Stock Offering
$61.7M
Stock Offering
$183.3M
Debt
$447.7M
Stock Offering
$250M
Stock Offering
$200M
Debt
$210.4M
Series B (2010): $25M supported by Genextra S.p.A
Series C (2012): $30M featuring OrbiMed and Genextra S.p.A
Stock Issuance/Offering (2012): $75M, investors not publicly disclosed
Stock Issuance/Offering (2013): $61.7M, investors not publicly disclosed
Stock Issuance/Offering (2014): $183.3M, investors not publicly disclosed
Debt (2016): $447.7M, investors not publicly disclosed
Stock Issuance/Offering (2018): $250M featuring Samsara BioCapital, L.P. and Genextra S.p.A
Stock Issuance/Offering (2019): $200M, investors not publicly disclosed
Debt (2019): $210.4M, investors not publicly disclosed
Key Investors in Intercept Pharmaceuticals
Genextra S.p.A
Genextra is a privately owned holding company that invests in early-stage life science companies, focusing on identifying innovative research to advance novel therapies and technologies.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm that utilizes deep research and advanced technology to identify opportunities across diverse financial markets.
What's next for Intercept Pharmaceuticals?
With the support of its recent major strategic investment, Intercept Pharmaceuticals is poised to accelerate its clinical development programs and expand its commercial footprint. The company's forward-looking strategy emphasizes the advancement of its pipeline candidates through critical regulatory milestones while optimizing its manufacturing and distribution networks. By maintaining a disciplined approach to capital allocation, Intercept aims to sustain its competitive advantage in the biopharmaceutical sector, focusing on long-term value creation for stakeholders and improved outcomes for patients suffering from chronic liver conditions. The integration of advanced research methodologies and strategic partnerships will remain central to its growth trajectory as it navigates the complexities of the global healthcare landscape.
See full Intercept Pharmaceuticals company page
